| |
|
|
|
| |
Harnessing Expression Testing for Drug Discovery Research
September 7, 2012 - Charles River has historically utilized real-time PCR for the purpose of zygosity testing of transgenic animals, single integration analysis, copy number determination and expression testing of an overexpressed gene. Our Genetically Engineered Models and Services (GEMS) team recently validated additional low density (TLDA) and mid-density (OpenArray®) expression testing platforms to support non-GLP drug discovery research for clients in the pharmaceutical sector. Expression testing can provide early signs of efficacy and toxicity, confirming or refuting theories for indication and therapeutic area.
Expression profiling data has proven useful in safety lead optimization and dose-limited toxicity studies. Utilizing our high-throughput platforms and pre-validated assays, GEMS can perform studies that involve multiple dose groups with samples from several organ systems, including liver, kidney, heart and skeletal muscle. This method allows us to assay a large number of target genes following treatment, providing clients with early indications of toxicity and efficacy before moving on to more intensive and costly studies of other species.
To learn more about how to leverage our expression testing services in your drug discovery research, email askcharlesriver@crl.com.
Related Information:
|
|
Expression, expression testing, OpenArray,, open array, PCR, non-GLP, efficacy, toxicity, GEMS, genetic testing, genetic, zygosit, biomarker, biomarkers, real-time PCR, Genetically Engineered Models and Services, TLDA, low density, mid-density
Harnessing Expression Testing for Drug Discovery Research | Charles River
Charles River recently validated additional applications of expression testing to support non-GLP drug discovery research, providing early signs of efficacy and toxicity.